TY - T1的血浆骨桥蛋白水平与认知之间的关系表现在复发多发性硬化症:Natalizumab治疗效果(P04.099) JF -神经学乔-神经病学SP - P04.099 LP - P04.099六世- 78 - 1补充非盟- Pietro Iaffaldano盟盟Maddalena Ruggieri罗莎吉玛Viterbo AU - M首页ariangela Mastrapasqua AU -达Paolicelli AU -古格列尔莫Lucchese AU -玛丽亚Trojano Y1 - 2012/04/25 UR - //www.ez-admanager.com/content/78/1_Supplement/P04.099.abstract N2 -目的:评估血浆骨桥蛋白之间的关系(pOPN)水平和认知表现之前和期间2年Natalizumab (NTZ)治疗复发多发性硬化症(名RRMS)患者。背景增加血浆和脑脊液(CSF) OPN水平报道患者MS,阿尔茨海默病和艾滋病痴呆。CSF明显下降的OPN水平在治疗NTZ最近名RRMS患者的描述。设计/方法:43名RRMS (33 F,平均年龄为34.3±10.4年,平均病程9.9±5.3岁,中位数3.5 eds(范围)[2.0 - -5.5])定于NTZ治疗和22岁——准确性健康对照组(高碳钢)登记。pOPN水平评估商业酶联免疫试剂盒在基线和血浆样本每2年6个月。认知的表现进行评估,通过短暂的可重复的电池,在基线和每12个月。全球认知损伤指数(CII)计算为每个病人。不同参数之间的相关性评估通过偏相关测试。结果:基线pOPN显著水平(Mann-Whitney测试;p = 02)高(65.13±22.91 ng / ml)名RRMS患者比高碳钢(53.20±12.68)。认知障碍(失败≥3测试)中检测出27.9%的名RRMS。在名RRMS患者中,基线pOPN水平显著相关(r =。59,p = 04) CII值(平均14; range 0-27). pOPN levels significantly (p=.036) decreased after 1(n=24; 56.19±17.63) and 2 (n=8; 36.87±8.71) years of NTZ treatment. Median CII significantly (p=.029) decreased during NTZ treatment to 9 (range 0-28) at year 1 and to 3.5 (range 0-18) at year 2. A significant correlation between the reduction of the CII and of the pOPN levels was found (r=.442; p=0.045) at year 1.Conclusions: these results suggest a possible role of OPN as a bridge protein between inflammation and neurodegeneration in RRMS and a beneficial effect of NTZ on cognitive performances partially related to a reduction of pOPN levels.Disclosure: Dr. Iaffaldano has nothing to disclose. Dr. Ruggieri has nothing to disclose. Dr. Viterbo has received personal compensation for activities with Biogen Idec and Novartis. Dr. Mastrapasqua has nothing to disclose. Dr. Paolicelli has received personal compensation for activities with Merck, Serono, Bayer Schering Pharma, and Biogen Idec. Dr. Lucchese has nothing to disclose. Dr. Trojano has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec and Sanofi-Aventis Pharmaceuticals, Inc. as a consultant and/or speaker. Dr. Trojano has received research support from Merck & Co., Inc.Wednesday, April 25 2012, 07:30 am-12:00 pm ER -